Randomized Phase II Study of Image-Guided Radiosurgery / SBRT for Localized Spine Metastasis

Chinese University of Hong Kong1 site in 1 country1 target enrollmentNovember 2010

ConditionsSpine Metastasis

Overview

Phase: Phase 2
Intervention: Not specified
Conditions: Spine Metastasis
Sponsor: Chinese University of Hong Kong
Enrollment: 1
Locations: 1
Primary Endpoint: Pain control at 3 months post-treatment
Status: Completed
Last Updated: 11 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

Demonstrate the technical feasibility of treating spine metastases with image-guided radiosurgery/SBRT

Registry

clinicaltrials.gov

Start Date

November 2010

End Date

July 2014

Last Updated

11 years ago

Study Type

Interventional

Study Design

Parallel

Sex

All

Investigators

Sponsor

Chinese University of Hong Kong

Responsible Party

Principal Investigator

CCTU

Comprehensive Clinical Trial Unit

Chinese University of Hong Kong

Eligibility Criteria

Inclusion Criteria

•The patient must have localized spine metastasis from the C1 to L5 levels by a screening imaging study (bone scan, PET, CT, or MRI). A solitary spine metastasis; two separate spine levels; or up to 3 separate sites are permitted. Each of the separate sites may have a maximal involvement of 2 contiguous vertebral bodies. A paraspinal mass ≤ 5 cm is allowed.
•Zubrod Performance Status 0-2;
•History/physical examination within 2 weeks prior to registration;
•No pregnancy for women of childbearing potential;
•MRI of the involved spine within 4 weeks prior to registration to determine the extent of the spine involvement. MRI is required as it is superior to a CT scan in delineating the spinal cord as well as identifying an epidural or paraspinal soft tissue component. If possible, an MRI with thin slice thickness (\<1mm) with 3D reconstruction quality would be most preferable for treatment planning purpose.
•Numerical Rating Pain Scale within 1 week prior to registration. The patient must have a score on the Scale of ≥ 4 for at least one of the planned sites for spine radiosurgery. Patients taking medication for pain at the time of registration are eligible.
•Neurological examination within 1 week prior to registration to rule out rapid neurologic decline; see Appendix IV for the standardized neurological examination. Patients with mild to moderate neurological signs are eligible. These neurological signs include radiculopathy, dermatomal sensory change, and muscle strength of involved extremity 4/5 (lower extremity for ambulation or upper extremity for raising arms and/or arm function).
•Patients with epidural compression are eligible provided that there is no significant displacement or compression on the spinal cord itself.
•Patients with a paraspinal mass ≤ 5 cm in the greatest dimension and that is contiguous with spine metastasis are eligible.
•Patients must provide study specific informed consent prior to study entry.

Exclusion Criteria

•Histologies of myeloma or lymphoma.
•Patients with any spine metastasis with a rating of \< 4 on the Numerical Rating Pain Scale.
•Non-ambulatory patients.
•Spine instability due to a compression fracture.
•\> 50% loss of vertebral body height.
•Significant spinal cord compression or displacement.
•Patients with rapid neurologic decline.
•Bony retropulsion causing neurologic abnormality.
•Prior radiation to the index spine.
•Patients for whom an MRI of the spine is medically contraindicated.

Outcomes

Primary Outcomes

Pain control at 3 months post-treatment

Time Frame: 4 years

Secondary Outcomes

Overall Survival(4 years)
Quality of life assessment(4 years)
Determine the duration of pain response at the treated site(s) using radiosurgery/SBRT(4 years)
Study the adverse events of radiosurgery/SBRT according to the criteria in the CTEP Active Version of the CTCAE(4 years)
Determine the time of onset of pain response of the responders at the treated site(s) using radiosurgery/SBRT(4 years)
Evaluate the radiological response of image-guided radiosurgery/SBRT by RECIST MRI(4 years)
2-year Tumor Control Rate(4 years)